@entity4269 prevalence and treatment benefits in XXXX : impact of a therapeutic intervention on health outcomes and costs.

@entity5 @entity1 @entity4269 @entity2850
BACKGROUND: @entity4269 is a common complication of @entity5 therapeutics; its prevalence, treatment outcomes, and costs have been poorly defined. The objective of this study was to examine @entity4269 prevalence among @entity5 survivors and to characterize changes in clinical outcomes and costs associated with a defined therapeutic intervention (use of a @entity2850 [ @entity2850 ]) in a representative, privately insured population. METHODS AND FINDINGS: Retrospective analysis of de-identified health claims data from a large national insurer for calendar years 2007 through 2013. @entity1 were required to have 12 months of continuous insurance coverage prior to @entity2850 receipt (baseline), as well as a 12-month follow-up period. Analyses were performed for individuals with @entity5 -related @entity4269 (n=1,065). @entity4269 prevalence was calculated: number of @entity1 with a @entity4269 in a calendar year divided by total number of enrollees. The impact of @entity2850 use was evaluated by comparing rates of a pre-specified set of health outcomes and costs for the 12 months before and after, respectively, @entity2850 receipt. @entity4269 prevalence among @entity5 survivors increased from 0.95% in 2007 to 1.24% in 2013. @entity2850 use was associated with decreases in rates of hospitalizations (45% to 32%, p<0.0001), outpatient hospital visits (95% to 90%, p<0.0001), cellulitis diagnoses (28% to 22%, p=0.003), and physical therapy use (50% to 41%, p<0.0001). The average baseline health care costs were high ( 53,422) but decreased in the year after @entity2850 acquisition (- 11,833, p<0.0001). CONCLUSIONS: @entity4269 is a prevalent medical condition that is often a defining attribute of @entity5 survivorship. The problem is associated with high health care costs; Treatment (in this instance, use of @entity2850 ) is associated with significant decreases in adverse clinical outcomes and costs.
